Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) EPS (Weighted Average and Diluted) (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with $4.23 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Weighted Average and Diluted) rose 132.29% year-over-year to $4.23, compared with a TTM value of -$2.45 through Dec 2025, up 88.3%, and an annual FY2025 reading of -$2.45, up 88.3% over the prior year.
  • EPS (Weighted Average and Diluted) was $4.23 for Q4 2025 at Aligos Therapeutics, up from -$3.04 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $4.23 in Q4 2025 and bottomed at -$32.82 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$4.15, with a median of -$0.84 recorded in 2022.
  • The sharpest move saw EPS (Weighted Average and Diluted) plummeted 6335.29% in 2023, then soared 284.09% in 2024.
  • Year by year, EPS (Weighted Average and Diluted) stood at -$0.78 in 2021, then skyrocketed by 34.72% to -$0.51 in 2022, then tumbled by 6335.29% to -$32.82 in 2023, then skyrocketed by 60.09% to -$13.1 in 2024, then surged by 132.29% to $4.23 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for ALGS at $4.23 in Q4 2025, -$3.04 in Q3 2025, and -$1.53 in Q2 2025.